title: NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice.
abstract: Peptide YY (PYY)(3-36), a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion. Based on this anti-secretory effect, NPY Y2 receptor agonists may be useful as novel anti-diarrheal agents, but anti-diarrheal efficacy has yet to be determined. We therefore examined the anti-diarrheal efficacy of PYY(3-36) and a selective Y2 receptor agonist, N-acetyl-[Leu28, Leu31]-NPY(24-36), in experimental mouse models of diarrhea. Intraperitoneal administration of PYY(3-36) (0.01-1mg/kg) and N-acetyl-[Leu28, Leu31]-NPY(24-36) (10mg/kg) significantly inhibited diarrhea (increase in wet fecal weight and diarrhea score) induced by dimethyl-prostaglandin E2, 5-hydroxytryptamine, and castor oil. Anti-diarrheal activities of PYY(3-36) and N-acetyl-[Leu28, Leu31]-NPY(24-36) were comparable to the effects of loperamide (1mg/kg), a widely used anti-diarrheal drug. To clarify the anti-diarrheal mechanisms of NPY Y2 receptor agonists, we investigated the effects of PYY(3-36) and N-acetyl-[Leu28, Leu31]-NPY(24-36) on intestinal fluid secretion and colonic transit. PYY(3-36) (1mg/kg) and N-acetyl-[Leu28, Leu31]-NPY(24-36) (10mg/kg) significantly reduced dimethyl-prostaglandin E2-induced intestinal fluid accumulation in conscious mice, suggesting that NPY Y2 receptor agonists inhibit diarrhea, at least in part, by reducing intestinal secretion. In addition, PYY(3-36) (0.01-1mg/kg) and N-acetyl-[Leu28, Leu31]-NPY(24-36) (10mg/kg) potently inhibited normal fecal output, suggesting that NPY Y2 receptor activation inhibits colonic motor function and NPY Y2 receptor agonists inhibit diarrhea partly by slowing colonic transit. These results indicate that NPY Y2 receptor agonists inhibit diarrhea in mice by not only reducing intestinal fluid secretion, but also slowing colonic transit, and illustrate the therapeutic potential of NPY Y2 receptor agonists as effective treatments for diarrhea.
authors.affiliation: Tsukuba Research Institute, Banyu Pharmaceutical Co, Ltd, Okubo 3, Tsukuba 300-2611, Japan.
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Moriya
authors.forename: Takashi
authors.initials: T
authors.lastname: Shirakura
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Hirose
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kanno
authors.forename: Jun
authors.initials: J
authors.lastname: Suzuki
authors.forename: Akio
authors.initials: A
authors.lastname: Kanatani
mesh_terms: D000818:Animals; D000930:Antidiarrheals / Q000494:pharmacology / Q000627:therapeutic use; D003967:Diarrhea / Q000188:drug therapy / Q000503:physiopathology; D004195:Disease Models, Animal; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D007419:Intestinal Secretions / Q000378:metabolism*; D008139:Loperamide / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010446:Peptide Fragments; D019894:Peptide YY / Q000494:pharmacology / Q000627:therapeutic use; D017476:Receptors, Neuropeptide Y / Q000819:agonists*
chemical_list: D000930:Antidiarrheals; D010446:Peptide Fragments; D017476:Receptors, Neuropeptide Y; C095889:neuropeptide Y2 receptor; D019894:Peptide YY; C061785:peptide YY (3-36); D008139:Loperamide